Brought to you by 
Pernix to sell Glaxo’s migraine product Treximet in the US
22 Jan 2016
Executive Summary
Only a few months after raising $60mm in financing to support new product acquisitions, spec pharma Pernix Therapeutics Holdings Inc. followed through and received US rights to GlaxoSmithKline PLC’s Treximet (naproxen/sumatriptan), a marketed NSAID/triptan for acute migraine with or without aura.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com